In the first half of the year, REIG JOFRE improved its EBITDA margin by 2.2 percentage points, doubled net profit and reached significant strategic milestones
Reig Jofre closed the first half of 2026 with revenue of €168.5 million, up 1% year-on-year, and EBITDA of €17.9 million, 27% higher than in the same period of 2025. The EBITDA margin reached 10.7% (8.5% in H1 2026), driven by strong performance in the osteoarticular...Reig Jofre accelerates its biopharmaceutical transformation, which began in 2018 with the integration of Leanbio
Reig Jofre is driving a strategic transformation from a traditional pharmaceutical company to a biopharmaceutical company, supported by the integration of Leanbio and Syna Therapeutics. This process began in 2018 with the acquisition of a stake in Leanbio and the...REIG JOFRE acquires Leanbio and strengthens its vertical integration in biotechnology
Reig Jofre has consolidated its stake in Leanbio by increasing its shareholding from 47% to 85%, following the acquisition of shares valued at €3.5 million. The remaining 15% remains in the hands of the founding team and specialised shareholders. This transaction is...